Navigation Links
Rheumatoid Arthritis Patients are Moderately to Highly Satisfied with Their Current Drug Therapy, Rating Conventional DMARDs Highest on Ease of Use and Cost
Date:5/29/2013

EXTON, Penn., May 29, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that rheumatoid arthritis patients are moderately to highly satisfied with the drugs, biologic and non-biologic, they are currently taking for their condition. Most of the surveyed patients indicate they are unlikely to request a change in therapy in the next year, supporting the finding that they are satisfied with their current medication.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36805LOGO)

The PatientTrends® Rheumatoid Arthritis (US) 2013 report finds that conventional disease-modifying antirheumatic drugs (DMARDs) are rated highest on ease of use and cost due to their oral formulations and generic availability. However, despite the fact that Pfizer's Xeljanz is a new oral agent, rheumatoid arthritis patients express a low likelihood to ask their doctor to prescribe Xeljanz, post-exposure to Xeljanz's profile. The high patient drug satisfaction finding is contrary to rheumatologists' views of the currently available rheumatoid arthritis drug treatments where, in the TreatmentTrends® Rheumatoid Arthritis (US) 2012 report, close to 50 percent of surveyed rheumatologists rated rheumatoid arthritis as a disease with a high unmet need for new drug therapies.   

"Approximately half of the surveyed rheumatoid arthritis patients taking conventional DMARDs and/or biologics do not experience any side effects," said BioTrends Senior Data Analyst Jen Dolga . "Therefore, if their current drug is working and they are not experiencing side effects, the patients are not going to ask their doctors to change their medication."

About BioTrends Research Group
BioTrends Research Grou
'/>"/>

SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA)
2. Patent Issued In U.S. For EntreMeds 2ME2 In Rheumatoid Diseases
3. AstraZeneca Announces Top-Line Results From OSKIRA-1 Phase 3 Study of Fostamatinib in Rheumatoid Arthritis
4. Specialty drug costs account for more than 50 percent of the total cost of care for rheumatoid arthritis and hepatitis C patients
5. Though Over One-Third of Rheumatologists Have Prescribed Xeljanz for Their Rheumatoid Arthritis Patients, Physicians are Still Concerned With the Drugs Limited Post-Marketing Experience and Risks of Infection and Malignancy
6. Lilly Discontinues Phase 3 Rheumatoid Arthritis Program for Tabalumab Based on Efficacy Results
7. Lilly Discontinues One of Three Phase 3 Rheumatoid Arthritis Registration Studies for Tabalumab
8. AstraZeneca Announces Top-Line Results of OSKIRA-4 Phase IIb Study of Fostamatinib as a Monotherapy for Rheumatoid Arthritis
9. UCB, Inc. and Arthritis Foundation Partner to Celebrate the "Everyday Victories" of the Rheumatoid Arthritis Community
10. Epidemiology: Rheumatoid Arthritis in China - Rapid urbanization presents favorable market potential
11. Phase 3 Data Show Intravenous Golimumab Inhibited Radiographic Progression in Patients with Active Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... YORK , July 29, 2014  Longtime industry ... Caremark Rx, Drew Crawford today announced the ... the leading independent media source dedicated to delivering fair, ... on the pharmacy benefit management (PBM) industry .  ... of, and context behind, industry news.   The outlet will ...
(Date:7/29/2014)... , July 29, 2014 McGraw-Hill Education Professional, ... the science, technical, and medical communities, has announced the ... off-line mobile application of the world-renowned medical education platform. ... AccessMedicine App , available for download onto all ... be able to gain access to valuable AccessMedicine ...
(Date:7/29/2014)... According to a new market ... Devices Market - Global Forecast, Market Share, Size, Growth ... trauma fixation devices market is estimated at USD 6.1 ... a CAGR of 7.2% from 2014 to 2019, to ... 2020. Browse the Orthopedic Trauma Fixation Devices ...
Breaking Medicine Technology:Drew Crawford Announces Launch of PBM365 Media 2McGraw-Hill Education Professional's AccessMedicine App Delivers Instant Access to Essential Diagnostic Tools 2McGraw-Hill Education Professional's AccessMedicine App Delivers Instant Access to Essential Diagnostic Tools 3Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 2Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 3Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 4
(Date:7/29/2014)... Los Angeles, CA (PRWEB) July 29, 2014 ... on the website of Time Magazine titled “From Kim’s ... Want,” Kim Kardashian’s butt is the celebrity ... celebrities and their features include Beyoncé’s butt, Jennifer ... and lips. This information is based on data collected ...
(Date:7/29/2014)... (July 29, 2014) Using quality improvement measures in ... England Cardiovascular Disease Study Group, researchers have found a ... procedure with contrast dye. , Currently, 7-15 percent of ... contrast-dye end up with kidney injury, which can result ... to temporary or permanent dialysis, says a study published ...
(Date:7/29/2014)... Gainesville, FL (PRWEB) July 29, 2014 Many ... very first thing they do each morning is put on ... the bathroom. These same individuals also may be dissatisfied ... cataracts. , Cataracts may cause difficulty driving, especially ... harder to follow or find one’s golf ball, see the ...
(Date:7/29/2014)... New high priced hepatitis C drugs will increase ... $2.9 to $5.8 billion next year, according to a ... by the Pharmaceutical Care Management Association (PCMA). Milliman projects ... much as 8.6 percent in 2015 as a result ... , The study finds that the majority of new ...
(Date:7/29/2014)... Alan Mozes HealthDay ... Treating certain adult autism patients with just a single dose ... facial expressions and emotions, Japanese researchers report. Known as ... role in emotional bonding between lovers, and between mothers and ... activity in a key area of the brain that has ...
Breaking Medicine News(10 mins):Health News:Celebrity Plastic Surgery: Kim Kardashian’s Butt Tops the List of Celebrity Plastic Surgery Requests 2Health News:Reducing kidney injury using a quality improvement method 2Health News:Cataract Surgery: New Technology for Reduced Dependence on Glasses 2Health News:New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2Health News:'Love Hormone' Oxytocin May Help Some With Autism 2Health News:'Love Hormone' Oxytocin May Help Some With Autism 3
... , , KENILWORTH, N.J., Aug. 6 ... live Webcast of its Special Shareholders Meeting being held on Friday, ... between Schering-Plough and Merck & Co., Inc. Originating from Boston, ... corporate Web site, www.schering-plough.com . , , ...
... exposure associated with skin inflammation in study of myositis ... ultraviolet (UV) rays may trigger certain types of autoimmune ... "This study found that women who lived in areas ... an autoimmune muscle disease called myositis were more likely ...
... ... Health Letter focuses on the feet and their common ailments. Dr. James Ioli, chief of podiatry ... ... of our feet. They provide a steady base when we stand, serve as shock absorbers when ...
... Aug. 6 Vitamin Shoppe Industries Inc., a leading specialty ... will hold a conference call for its bondholders on Thursday, ... call, members of management will report on the Company,s second ... To participate in the teleconference, bondholders are invited to call ...
... BEIJING and BETHESDA, Md., Aug. 6 /PRNewswire-Asia/ -- ... ("Chindex") (Nasdaq: CHDX ), a leading,independent ... in,the People,s Republic of China, today announced that ... plans to,launch a comprehensive, international-standard oncology program, called ...
... , , SAN DIEGO, Aug. 6 AMN Healthcare Services, Inc. (NYSE: AHS ) today announced ... 2009 include: , , ... % Chg % Chg, ... Q2 2009 Q2 2008 Q1 2009, ------------------------------------------------------------, ...
Cached Medicine News:Health News:Sunlight May Cause Rash in Autoimmune Disease 2Health News:Harvard Health Letter Special Section Features the Body's Unsung Marvels: The Feet 2Health News:Chindex International, Inc. Launches World-Class Cancer Treatment Center 2Health News:Chindex International, Inc. Launches World-Class Cancer Treatment Center 3Health News:Chindex International, Inc. Launches World-Class Cancer Treatment Center 4Health News:AMN Healthcare Announces Second Quarter 2009 Results 2Health News:AMN Healthcare Announces Second Quarter 2009 Results 3Health News:AMN Healthcare Announces Second Quarter 2009 Results 4Health News:AMN Healthcare Announces Second Quarter 2009 Results 5Health News:AMN Healthcare Announces Second Quarter 2009 Results 6Health News:AMN Healthcare Announces Second Quarter 2009 Results 7Health News:AMN Healthcare Announces Second Quarter 2009 Results 8Health News:AMN Healthcare Announces Second Quarter 2009 Results 9Health News:AMN Healthcare Announces Second Quarter 2009 Results 10Health News:AMN Healthcare Announces Second Quarter 2009 Results 11Health News:AMN Healthcare Announces Second Quarter 2009 Results 12Health News:AMN Healthcare Announces Second Quarter 2009 Results 13Health News:AMN Healthcare Announces Second Quarter 2009 Results 14Health News:AMN Healthcare Announces Second Quarter 2009 Results 15Health News:AMN Healthcare Announces Second Quarter 2009 Results 16
Blunt, fine curved shaft hook to unroll membranes. 24 gauge shaft with dark finish for reduced glare....
0.2 mm hook with curved shaft to reach over lens optic. Flat serrated handle with polished finish. Overall length: 4.8 inches. Most popular size or model....
Angled 45 degrees, 10 mm shaft with 0.2 mm tip. Round knurled handle with dull finish. Overall length: 4.6 inches....
Straight 31 mm shaft with flat handle and polished finish. 0.5 mm cup. Overall length: 5 inches....
Medicine Products: